Trevor Bentley

Io Therapeutics (United States) — United States

Medicine · Health Sciences

10h-index469citations22works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(8), Viral Infectious Diseases and Gene Expression in Insects(6), Neonatal Respiratory Health Research(3), Barrier Structure and Function Studies(3), Biosimilars and Bioanalytical Methods(3)

Publications22 total

CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies
Blood·2024· 3 citedOpen Access
Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models
Science Advances·2023· 17 citedOpen Access
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
Cancer Research Communications·2022· 39 citedOpen Access
Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma
Blood·2020· 10 cited
Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups
Blood·2019· 3 cited
Off-the-shelf AlloCAR T™ cells targeting BCMA for the treatment of multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2019· 3 cited
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma
Molecular Therapy·2019· 156 citedOpen Access
ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma
Blood·2018· 16 cited
Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia
Blood Advances·2018· 20 citedOpen Access
Identification of IRF8 As a Potent Tumor Suppressor in Murine Acute Promyelocytic Leukemia
Blood·2016
Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses
Journal for ImmunoTherapy of Cancer·2015· 2 citedOpen Access
Abstract 255: Dual targeting of Delta-like ligand 4 (DLL4) and programmed death 1(PD1) inhibits tumor growth and generates enhanced long-term immunological memory
Cancer Research·2015· 2 cited
Claudin-18 Deficiency Results in Alveolar Barrier Dysfunction and Impaired Alveologenesis in Mice
American Journal of Respiratory Cell and Molecular Biology·2014· 112 citedOpen Access
Double impact of cigarette smoke and mechanical ventilation on the alveolar epithelial type II cell
Critical Care·2014· 16 citedOpen Access
Claudin‐4 promotes epithelial repair and restoration of barrier function via interactions with the small GTPase Rap1
The FASEB Journal·2013
A Role For Lung-Specific Tight Junction Protein Claudin-18 In Alveolar Epithelial Barrier Function
2012· 1 cited
Claudin‐4 interacts with the small GTPase Rap1 and accelerates epithelial repair
The FASEB Journal·2012
Caloric restriction influences hydrogen peroxide generation in mitochondrial sub-populations from mouse liver
Journal of Bioenergetics and Biomembranes·2011· 29 cited
A Study of the Representation of Pakeha-Maori by Historians of New
2007
Images of Pakeha-Māori: A Study of the Representation of Pakeha-Māori by Historians of New Zealand From Arthur Thomson (1859) to James Belich (1996)
Research Commons (University of Waikato)·2007· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Cesar Sommer(7), Barbra J. Sasu(7), Janette Sutton(5), James A. Frank(5), Bijan Boldajipour(4), Thomas Van Blarcom(4), Michael J. LaFemina(4), Katherine Sutherland(4), Julien Valton(3), Yajin Ni(3), Julianne Smith(3), Román Galetto(2), Javier Chaparro‐Riggers(2), Lennell Allen(2), Deepti Rokkam(2), Leland G. Dobbs(2), Ana M. Metelo(2), Agnieszka Jóźwik(2), Charlotte Graham(2), Charlotte Attwood(2)